TITLE

The Industry

PUB. DATE
December 2006
SOURCE
Pharmaceutical Representative;Dec2006, Vol. 36 Issue 12, p10
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers global news briefs related to pharmaceutical industry. UCB Group Ltd. has offered €4.4 billion to acquire Schwarz Pharma AG. Roche Pharmaceuticals and InterMune Inc. have agreed to collaborate in the development and commercialization of hepatitis C virus protease inhibitors. NitroMed Inc. is planning to dismantle its current sales force.
ACCESSION #
23291198

 

Related Articles

  • Roche: strengthening its HCV pipeline.  // PharmaWatch: Monthly Review;Dec2006, Vol. 5 Issue 12, p24 

    The author reflects on the move of pharmaceutical company Roche Pharmaceuticals to collaborate with InterMune Inc. in developing an inhibitor for Hepatitis C virus (HCV). According to the author, the drive will strengthen the status of Roche to the HCV market in the face of strong competition...

  • Intermune up on buyout buzz. Investor's Business Daily // Investors Business Daily;8/14/2014, pA02 

    The article reports on the potential buyers of biotechnology company InterMune including drugmakers Roche, Sanofi, and GlaxoSmithKline.

  • Roche's $8.3B InterMune buy continues its buying spree with 'bolt-on' deal, fueling record M&A activity. Rosenberg, Ronald // CenterWatch Weekly;9/2/2014, Vol. 18 Issue 34, p1 

    The article reports that global pharmaceutical company F. Hoffmann-La Roche Ltd. has continued its targeted buying spree by paying $8.3 billion for idiopathic pulmonary fibrosis (IPF) drug developer InterMune Inc. It mentions that the deal follows a record of six months of mergers and...

  • Roche.  // Formulary;Oct2000 Resource Guide, Vol. 35 Issue 10, p83 

    Features the Roche Holding Ltd., a pharmaceutical manufacturer. Focus of its international research and development efforts; Total shares at the biotechnology company, Genentech Inc.; Pharmaceutical products that have received approval from the United States Food and Drug Administration.

  • Legal costs batter Roche's profits. Beacham, Will // European Chemical News;3/3/2003, Vol. 78 Issue 2042, p9 

    Reports the financial performance of Swiss pharmaceutical company Roche in 2002. Factors that influenced its financial performance; Overview of its financial results; Expectations for 2003.

  • Global Report.  // Pharmaceutical Representative;Nov2011, Vol. 41 Issue 11, p10 

    The article offers information related to the pharmaceutical industry such as the end of the deal to supply drugs between Roche and the state-funded hospitals in Greece, and the adoption by the European Commission (EC) of the revised proposals on supplying prescription-only drugs to the public.

  • It's Roche vs Schering-Plough for hepatitis-C market.  // Medical Marketing & Media;Nov2002, Vol. 37 Issue 11, p10 

    Reports on Roche AG's receipt of U.S. Food and Drug Administration approval for Pegasys, a drug for treatment of hepatitis C. Marketing program; Competition with PEG-Intron from Schering-Plough.

  • Roche's Pharma Pipeline Beginning to Blossom. Jarvis, Lisa // Chemical Market Reporter;9/3/2001, Vol. 260 Issue 9, p12 

    Presents information on potentially important products from Roche's pharmaceutical division as a result of improvements made in the research and development approach. Overview on Roche's hepatitis C treatment Pegasys; Company's cycle cell inhibitor for the treatment of solid tumors; Roche's...

  • Healthy combo.  // Business News New Jersey;10/02/96, Vol. 9 Issue 20, p3 

    Focuses on the business partnership formed between Bayer AG's Consumer Care Division and Roche Holding AG to market a batch of the firms' over-the-counter drugs.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics